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Abstract 
In patients undergoing hematopoietic stem
cell transplantation (HSCT), refractoriness to
platelet transfusion has been associated with
graft failure, delayed engraftment, early mor-
tality and decreased overall survival.
Therapeutic strategies include plasma
exchange, immunoglobulins, rituximab, and
splenectomy. We describe here three patients
with refractoriness to platelet transfusion due
to anti-human leukocyte antibodies who were
splenectomized before HSCT (two cases) and
after HSCT (one case) due to the lack of effica-
cy of other therapies. Splenectomy was
uneventful. All three patients achieved a full
donor engraftment. We suggest that splenecto-
my is feasible and effective in HSCT patients
to reduce the risk of graft failure or delayed
engraftment. 
Introduction
Immune-mediated refractoriness to platelet
transfusions is observed in patients who
receive non-leukodepleted hemocomponents
and develop anti-HLA antibodies.1,2 This com-
plication may have a negative impact on the
success of a hematopoietic stem cell transplant
(HSCT) because it has been related to graft
failure.3-7 Moreover, the presence of anti-HLA
antibodies has been associated with a delay in
the time of neutrophil and platelet engraft-
ment, early mortality and decreased long-term
overall survival.5 The presence of a spleen and
the number of anti-HLA antibodies were the
factors that predict the yield of platelet transfu-
sion in HSCT patients.8
Therapeutic strategies for platelet transfu-
sion refractoriness include removing the exist-
ing antibodies by plasma exchange, inhibiting
antibody activity by immunoglobulin, and
blocking B cells or plasma cells by rituximab.9
Splenectomy can improve the yield of platelet
transfusion although it does not alter the num-
ber and type of anti-HLA antibodies.8
We describe three patients who developed
refractoriness to platelet transfusion due to
anti-HLA antibodies before HSCT who were
successfully managed by splenectomy. Table 1
shows the main demographic and clinical
characteristics of the three patients. 
Case Report #1
K.L. is a 3-year-old female from Georgia diag-
nosed with myelodysplastic syndrome who was
treated mainly with supportive prophylactic non-
leukodepleted platelet and red cell transfusions
for 19 months until she was referred to our cen-
ter for an allogeneic HSCT. At admission, she
presented with refractoriness to platelet transfu-
sion. The search of anti-HLA antibodies showed
the presence of anti-HLA class I (ELISA PakAuto
and Quick Screen; GTI Diagnostics, Brookfield,
WI, USA). The patient was treated initially with
two courses of intravenous immunoglobulins
(0.8 g/kg) followed by four courses of dexam-
ethasone (4×40 mg/day) and rituximab (4×375
mg/m2).10 These therapies did not result in sig-
nificant increment of post-transfusion platelet
count so, after three months, a laparoscopic
splenectomy was decided upon, preceded by vac-
cination for capsulated bacteria (one dose of 23-
valent pneumococcal polysaccharide vaccine,
one dose of 4-valent polysaccharide meningo-
coccal vaccine and one dose of hemophilus B
conjugate vaccine). Splenectomy was unevent-
ful and the patient was discharged after 8 days.
The platelet count increased from 12×109/L pre-
surgery to 51×109/L two days after splenectomy.
The median transfusion-dependency dropped
from three transfusions/week before surgery to
none after splenectomy. Five months after
splenectomy, the patient underwent an unma-
nipulated haploidentical stem cell transplant. A
stable neutrophil count >0.5×109/L and a
platelet count >50×109/L were achieved after 16
and 42 days from transplant, respectively. The
patient was discharged on day + 19 post-HSCT.
After 11 months from HSCT the patient is well
(Lansky play score 100%), in amoxicillin prophy-
laxis and in complete hematological remission
with blood count always within the normal range
and full donor chimerism. The  maximum count
of platelet reached after splenectomy was
342×109/L. 
Case Report #2
T.Z. is an 8-year-old male from Georgia diag-
nosed with myelodysplastic syndrome and
treated supportively for 8 months with non-
leukodepleted platelet and red cell transfu-
sions until he was referred to our center for
allogeneic HSCT. At admission, the patient had
refractoriness to platelet transfusion and the
search for anti-HLA class I antibodies was pos-
itive (ELISA PakPlus; Gen Probe Diagnostics,
San Diego, CA, USA). The patient was treated
with three courses of intravenous
immunoglobulins (0.8 g/kg), followed by four
courses of dexamethasone (4×40 mg/day) and
rituximab (4×75 mg/m2).10 After 4 months,
due to the persistence of a high dependency to
platelet transfusions, the patient underwent a
laparoscopic splenectomy preceded by vaccina-
tion for capsulated bacteria (one dose of 23-
valent pneumococcal polysaccharide vaccine,
one dose of 4-valent polysaccharide meningo-
coccal vaccine and one dose of hemophilus B
conjugate vaccine). The operation was
uneventful and the patient was discharged
after 9 days. The platelet count was 4×109/L
pre-surgery and increased to 19×109/L seven
days after splenectomy. Before surgery, the
median requirement was two-platelet transfu-
sions/week, whereas after splenectomy the
patient required no further transfusions. One
month after splenectomy, the patient under-
went a haploidentical stem cell transplant.
Neutrophil and platelet engraftment occurred
14 days and 27 days, respectively and the
patient was discharged on day + 27 post-HSCT.
At the last follow-up, at + 18 months after
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HSCT, the patient is well, active (Lansky play
score 90%), in amoxicillin prophylaxis  and in
complete hematological remission with blood
count always within the normal range and full
donor chimerism. The  maximum count of
platelet reached after splenectomy was
491×109/L. 
Case Report #3
V.B. is a 6-year-old male from Ukraine, diag-
nosed with Juvenile Myelomonocytic
Leukemia (JMML) who was treated with
hydroxyurea, four courses of cytarabine, and
supportive care including non-leukodepleted
transfusions for 8 months until he was
referred to our center for an unrelated HSCT.
Before HSCT, the patient presented with
refractoriness to platelet transfusions that was
initially attributed to his underlying disease
with splenomegaly (+ 4 cm below left costal
margin), but subsequently it was considered
the result of allo-immunization because the
search for HLA antibodies class I and anti-
GPIb/IX, GPIa/IIa and GP IIb/IIIa (ELISA Pak 12;
GTI Diagnostics, Brookfield, WI, USA) resulted
positive. Because the HSCT was already sched-
uled it was decided to proceed, modifying the
conditioning regimen by adding a course of
plasma exchange, a course of rituximab
(1×375 mg/m2) with high dose intravenous
methylprednisolone (500 mg/m2/week) and
splenic irradiation. Neutrophil engraftment
occurred at day +22 after transplant whereas
platelet engraftment did not occur and the
patient remained transfusion-dependent with
a median requirement of four transfusions
/week. Given the persistence of splenomegaly,
on day + 91 post-HSCT, a laparoscopic splenec-
tomy was carried out. The surgery was
uneventful and the patient was discharged
after three weeks. Thirty-five days after
splenectomy, the platelet count was 186×109/L
with a maximum of 428×109/L two months
later.  At 10 months post-HSCT, the patient is
well (Lansky play score 100%), in amoxicillin
prophylaxis and in complete hematological
remission with blood count always within the
normal range and full donor chimerism. 
Discussion 
Platelet refractoriness may occur through a
non-alloimmune or an alloimmune mecha-
nism, the latter being caused by sensitization
to foreign Class I HLA and, less frequently, to
human platelet polymorphic antigens (HPA).11
This complication has been reported in
between 7-34% of patients with hematological
or oncological diseases, especially in patients
who do not receive leuko-depleted or irradiated
hemoproducts.11,12 In a randomized trial, the
use of leukodepletion or ultraviolet B irradia-
tion of platelets decreased alloimmunization
from 13% to 3% and 5%, respectively.13 All
three patients described here came from cen-
ters where leukodepletion and/or irradiation of
blood products were not routinely performed. 
The management of platelet refractoriness
is based on the modification of the type of
platelet product administered or on the modifi-
cation of the patient immune response. In the
first case, the selection of an HLA-matched
donor gives the highest post-transfusion
platelet increment but it requires the availabil-
ity of a large pool of dedicated HLA-typed
donors. The process of donor selection is time-
consuming without the certainty of finding a
matched donor; this procedure is also not ideal
for urgent management of bleeding.
Alternatively, a platelet cross-matching test
with patient serum can be used to more rapidly
identify the best platelet unit available.14 In
our center, both procedures were not feasible
because of an inadequate size of donor pool
and the inability to perform HLA screening on
every donor, so that the only feasible procedure
to improve the platelet transfusion yield was to
use platelet units derived from a pool of
donors. However, this policy did not result in a
significant reduction of transfusion frequency,
which remained on a daily or two-daily basis.
The modification of immune response by high-
dose of steroids, immunoglobulins and ritux-
imab was not associated with any improve-
ment of patient transfusion-dependency.
Considering that HLA sensitization can be a
major obstacle to successful engraftment in
HSCT,6 and may lengthen the period of trans-
fusion-dependency, increasing the risk of
severe bleeding episodes,15 we opted for
splenectomy. Despite the low number of
platelets at surgery, the laparoscopic procedure
was well tolerated without any significant
bleeding. This allowed the first two patients to
undergo myeloablative chemotherapy and to
engraft both for neutrophils and platelets with-
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Table 1.  Main demographic, clinical, and transplant characteristics of three patients. 
                                                               First case                                             Second case                                             Third case
Gender                                                                    Female                                                                   Male                                                                             Male
Country of origin                                                  Georgia                                                                  Georgia                                                                       Ukraine
Underlying disease                                              Myelodysplasia                                                    Myelodysplasia                                                          JMML
Age at diagnosis, years                                        3                                                                              8                                                                                   6 
Type of donor                                                        Haploidentical mother                                       Haploidentical mother                                            HLA matched unrelated donor (10/10)
Myeloablative conditioning regimen               BU 3×3.2 mg/kg/day; TT 1×5 mg/kg/day;         TBI 2 Gy; BU 3×3.2 mg/kg/day;                               RT 2 Gy (on spleen); 
                                                                                 Flu 3×50 mg/m2/day                                            TT 2×5 mg/kg/day; Flu 3×50 mg/m2/day               BU 4 3.8 mg/kg/day;
                                                                                                                                                                                                                                                        ATG 3×3.75 mg/kg/day; 
                                                                                                                                                                                                                                                        Cy 2×60 mg/kg/day; 
                                                                                                                                                                                                                                                        Mel 1×140 mg/m2/day 
GVHD prophylaxis                                                Tacrolimus/cyclosporine;                                  Tacrolimus/ cyclosporine;                                      Intravenous cyclosporin 3 mg
                                                                                 Cy 2×50 mg/kg/day (day + 3 and +4);            Cy 2×50 mg/kg/day (day + 3 and +4);                  kg/day; MTX  15 mg/m2 day + 1;  
                                                                                 MMF                                                                       MMF                                                                             MTX 10 mg/m2 day + 3, +6, +11
Number of infused CD34+ cells                       4.68×106/kg                                                            5.32×106/kg                                                                 4.16×106/kg
Neutrophil engraftment (>0.5×109/L)            + 16 days                                                               + 14 days                                                                    + 22 days 
Platelet engraftment (>50×109/L)                  + 42 days                                                               + 27 days                                                                    + 105 days after splenectomy
Blood count at last follow up                            + 11 months; Hb 12.9 g/dL;                                + 18 months; Hb 14.7 g/dL; PLT 500×109/L;         + 10 months; Hb 14.2/g/dL; PLT 
                                                                                 PLT 319×109/L; WBC 11.8×109/L                       WBC 13.2×109/L (neutrophils 4.3×109/L)           428×109/L; WBC 10.6×109/L (neutrophils
                                                                                 (neutrophils 3.1×109/L)                                                                                                                           4×109/L)
JMML, juvenile myelomonocytic leukemia; TBI, total body irradiation; RT, radiation therapy; BU, busulfan; TT, thiotepa; Mel, melphalan; Flu, fludarabine; ATG, anti-thymocyte globulin; Cy, cyclophosphamide; MTX, metothexate; MMF, mycophe-
nolate mofetil.
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out any significant delay in the first two cases
described. Interestingly enough, the third
alloimmunized patient did not engraft normal-
ly for platelets, despite the modification of the
conditioning regimen with the addition of
plasmapheresis, dexamethasone, rituximab
and splenic radiotherapy, and continued to be
platelet transfusion-dependent until splenecto-
my was performed at three months after trans-
plant. Marktel et al. showed that myeloablative
and immunosuppressive conditioning before
HSCT was not able to modify the number and
specificities of anti-HLA antibodies in eight
alloimmunized patients who rejected their
graft.8 On the contrary, in a thalassemic
alloimmunized patient who had a secondary
graft failure, a splenectomy before the second
HSCT did result in higher platelet transfusion
increment than the first HSCT (P=0.03).
Splenectomy, though not altering the anti-HLA
antibody production, can limit its negative
impact on the life of both exogenous and
endogenous platelets. This finding is in line
with the data reported recently by Palandri et
al.16 who showed that in patients with steroid-
refractory immune thrombocytopenia, splenec-
tomy had a response rate of 88.5% after a
median follow-up of 20 years; moreover, the
response rate was similar to or even higher
than rituximab in patients with non-splenic
uptake of platelets.    
Conclusions
In conclusion, in alloimmunized patients,
laparoscopic splenectomy is a valuable option
before HSCT to prevent graft failure, speed
platelet engraftment and reduce transfusional
burden after HSCT in patients with anti-HLA
antibodies. Further studies and longer follow-
up is needed to assess the impact of this
choice on long-term infectious morbidity.
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